

Service Specification Template – 2024/25

Service Name & Number	Universal Offer – LNRH Antagonist UO7LNRH
Population and / or geography to be served	The service shall be available to all patients registered with a GP Practice within the agreed Primary Care Network (PCN) to whom the commissioner is responsible for providing services to.
Service aims and desired outcomes	<p>The Provider shall record all activity using the Universal Offer clinical template.</p> <p>Aims and objectives of service</p> <ul style="list-style-type: none"> • The Provider shall support the administration of androgen deprivation administration in order to support delivery in primary care for improved patient care closer to home. • The Provider shall provide a service designed, with trained staff and appropriate facilities, to ensure sufficient resources are available in primary care to deliver services in a sustainable and clinically accountable fashion.
Service description and location(s) from which it will be delivered	<p>The Provider shall administer of one of the following gonaderelins for a licensed indication of the product as listed in section 3.2.1.:</p> <ul style="list-style-type: none"> • Goserelin (Zoladex® 3.6 mg implant and Zoladex® LA 10.8 mg) • Leuprorelin (Prostap® 3 DCS and Prostap® SR DCS) • Triptorelin (Decapeptyl® SR 3mg, Decapeptyl® SR 11.25mg, Decapeptyl® SR 22.5mg) <p>Information on the licensed indications of these drugs is provided in appendix 1 however the most up-to-date product Summary of Product Characteristics (SmPC) is the most complete source of information.</p> <p>Specialists should initiate treatment and provide clinical information to the GP practice. Patients should remain under specialist care for management of their condition and advice on dose changes or discontinuation of treatment will be provided to the Provider.</p> <p>It is a requirement of this Local Enhanced Service that the Provider:</p> <ul style="list-style-type: none"> • Provides a register - The Provider will need to produce and maintain a valid up-to-date register of patients being treated as part of this enhanced service. • Demonstrates a call and recall system - The Provider will need to ensure a systematic call and recall of patients on this register is taking place, and have in place the means to identify and follow up patients in default. • Support the education of both newly diagnosed patients and those with established disease - The secondary care specialist teams will provide the main source of advice for both newly diagnosed patients and those with established disease. The Provider will reinforce and supplement that advice where appropriate to do so. • Maintains accurate records – The Provider is to maintain adequate records of the service provided, incorporating all known information relating to any significant events e.g. adverse reactions, hospital admissions and relevant deaths of which the practice has been notified.

	<ul style="list-style-type: none"> • Ensures individual treatment plans are in place – Clear clinical information should be provided by the specialist which detail the indication, agreed treatment programme and the planned duration of treatment. The Provider should ensure these are documented in the patients' medical records. • Ensure primary care staff training - The Provider must ensure that all staff involved in providing any aspect of care under this scheme have the necessary training and skills to do so. Practices should be able to demonstrate that they have in place a policy to cover staff training and maintenance of skills which includes a register of trained staff to administer androgen deprivation treatments under this service. <p>The service is to be delivered from the GP practice or from another practice or appropriate healthcare setting within the Primary Care Network (PCN) where the practice is providing on behalf of the PCN.</p>
Service Model	<p>Any acceptance and exclusion criteria and thresholds</p> <p>The service is to be available to all patients meeting the following criteria:</p> <ul style="list-style-type: none"> • Registered practice patients • Able to attend surgery premises • Who have an indication for androgen deprivation therapy <p>The administration of gonaderelins for use in precocious puberty, assisted reproduction and gender identification disorder/dysphoria are not included within this service.</p>
Tariff	£17 per injection
Reporting and Payment	<p>You are required by the ICB to use UO resources provided by the ML Data Quality Team to support the recording of patient data and reporting for the UO services.</p> <p>A clinical template written by ML Data Quality Team (DQT) has been provided for recording patient data for services delivered as part of the Universal Offer (UO). The template has been validated by ICB clinical leads and built to ICB service specifications to support the UO service pathway. The clinical template will also help to demonstrate that the UO specified pathway has been used to deliver patient care.</p> <p>Using the clinical template will ensure the UO searches and claim reports (provided by the DQT) are populated correctly and submitted claims can be validated by the ICB against reports the ICB receive from the Data Quality Team. Where payment is made via RTP files, the report provided to the ICB will assist the ICB to validate the expected activity levels from the provider for that UO service.</p> <p>For EMIS practices the UO clinical templates are published centrally via Resource Publisher and will be maintained and updated by the DQT as and when required and will also reflect any Snomed code changes that may be required. Associated searches and reports will be updated where necessary and made available for use and practices will be notified of updates. For TPP S1 practices, the clinical templates are maintained and updated for you by your Data Quality Specialist.</p> <p>Various guidance documents to support using the resources provided by the ML DQT for the UO services are available from the GP365 website Universal Offer (sharepoint.com) or you can contact your Data Quality Specialist for any queries regarding use of the DQT resources or any training</p>

	<p>requirements related to use of the UO clinical templates or UO searches & reports.</p> <p>If the activity is not coded correctly, it will not be paid for.</p>
Review Date	January 2027
Termination Notice Period	3 years with a six-month notice period for termination. The service specification will be subject to regular review.
Applicable quality requirements and Accreditation Requirements	<p>Applicable standards set out in Guidance and/or issued by a competent body (e.g. Royal Colleges)</p> <p>Summary of Product Characteristics (SmPC) is to be used for information on the licensed indications of these drugs.</p> <p>For the most up-to-date licensing information please refer to each products' Summary of Product Characteristics (SmPC) available on the Electronic Medicines Compendium (eMC) (www.medicines.org.uk)</p>